Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome
about
Enzyme replacement therapy for Anderson-Fabry diseaseDevelopment of a highly sensitive immuno-PCR assay for the measurement of α-galactosidase A protein levels in serum and plasmaFabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?Human Alpha Galactosidases Transiently Produced in Nicotiana benthamiana Leaves: New Insights in Substrate Specificities with Relevance for Fabry DiseaseDepletion of globosides and isoglobosides fully reverts the morphologic phenotype of Fabry diseaseMigalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients.Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study.Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document.Rapid Immunochromatographic Detection of Serum Anti-α-Galactosidase A Antibodies in Fabry Patients after Enzyme Replacement Therapy.Effect and Tolerability of Agalsidase Alfa in Patients with Fabry Disease Who Were Treatment Naïve or Formerly Treated with Agalsidase Beta or Agalsidase Alfa.Innate and Adaptive Immune Response in Fabry DiseaseSerum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease.Variations in the GLA gene correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma.Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain.Fibrosis: a key feature of Fabry disease with potential therapeutic implicationsNatural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages.Treatment of lysosomal storage disorders: successes and challenges.Enzymes approved for human therapy: indications, mechanisms and adverse effects.Unravelling the mechanism of action of enzyme replacement therapy in Fabry disease.Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease.Renal function predicts long-term outcome on enzyme replacement therapy in patients with Fabry disease.A comparison study of bioanalytical methods for detection and characterization of anti-velaglucerase alfa antibodies.Long-Term Dose-Dependent Agalsidase Effects on Kidney Histology in Fabry Disease.Plasma lyso-Gb3: a biomarker for monitoring fabry patients during enzyme replacement therapy.Fabry disease under enzyme replacement therapy-new insights in efficacy of different dosages.Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study.Lucerastat, an Iminosugar for Substrate Reduction Therapy: Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Fabry Disease on Enzyme Replacement.A comparison study of bioanalytical methods for characterization of anti-idursulfase antibodies.Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients.Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRYGlucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation typesNeutralizing anti-drug antibodies in Fabry disease have no obvious clinical impact?
P2860
Q26471010-6539DCAB-C751-445E-90C5-5120B2A924D5Q28535053-C839B712-47CF-4A01-AAAD-A1014F099767Q33645550-59C5AEDD-3484-4AB6-86D9-BD895ADA75D0Q33819347-C82102CD-10C3-4F3A-A138-35034A6266D9Q34294988-0A612415-FBA7-44C9-A953-CFCF15A6D51FQ34614418-9E77261A-12CD-49AE-AC9E-7AC372BD5560Q34659532-6E88F2B0-6B29-4A9E-9C40-603B7240186EQ35247511-542A87EC-774D-4B98-A9B4-A7D57D19F49FQ35665871-184A6517-0909-4C76-8A70-24F49DFC97FAQ35795427-D8E040D4-EB42-4539-8A23-7BABA06B92F6Q35800976-A69B9508-9056-4E17-A117-71CFDD8950E1Q36417918-E4363259-B07D-4FA9-94C3-59BE663D446AQ36691965-ECB078A5-34A1-435B-9A52-6E1F25ED0FEEQ36767452-86003B7B-2DAF-4FB1-AE7F-6F29E07BD14EQ37113004-27873861-9627-49FE-913C-C09EAFDA726AQ38184922-92B6BB05-1A39-4347-B00D-4FA6DB3D7ED9Q38211269-4D3EDE2B-8504-46D6-B084-7BB4D6754BFEQ38342838-85CD7F25-A90D-4AAA-A6AE-654C7C56E122Q38421318-AB52BB50-D31E-4896-8E9D-DFF9BCA0ACAFQ38662053-22E35937-7E71-4421-B907-602E26C4F64DQ39344648-5EEB9435-0C9E-4EDF-9E2B-B82D6D4BD2AFQ47868198-1D01C848-F7AF-4B74-8746-BF7831C9F361Q48632125-FAE98348-8233-4436-9A77-FCB74B25720BQ49484334-C3116585-DF41-41D3-84AA-3D6B7C990CC5Q49548756-D5F49E25-E0CB-4C38-9131-D3319E82CAD9Q50043588-2E3CE0FC-8B0D-496C-85AD-D505DBB3E26FQ51842157-EF47F6C5-9ED4-4924-B550-10918D4C5532Q52553010-D95C8A9A-1BD1-441B-8EB8-D15E90E7CD95Q53099040-A572AF34-BC8E-4880-9689-EBF3AE5356B9Q57174028-7B0379CD-D455-4F55-80C6-ED5E77015AD6Q58794894-65408810-4590-4073-B131-EF96ECEFF35EQ58795662-3D13A0BE-A7F0-4CD1-A7E1-22106A1A9BCD
P2860
Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Long-term effect of antibodies ...... eduction and treatment outcome
@ast
Long-term effect of antibodies ...... eduction and treatment outcome
@en
Long-term effect of antibodies ...... disease on plasma and urinary
@nl
type
label
Long-term effect of antibodies ...... eduction and treatment outcome
@ast
Long-term effect of antibodies ...... eduction and treatment outcome
@en
Long-term effect of antibodies ...... disease on plasma and urinary
@nl
prefLabel
Long-term effect of antibodies ...... eduction and treatment outcome
@ast
Long-term effect of antibodies ...... eduction and treatment outcome
@en
Long-term effect of antibodies ...... disease on plasma and urinary
@nl
P2093
P2860
P1433
P1476
Long-term effect of antibodies ...... eduction and treatment outcome
@en
P2093
Ben J H M Poorthuis
Carla E M Hollak
Erik Hendriks
Frits A Wijburg
Gabor E Linthorst
Johanna E M Groener
Johannes M F G Aerts
Mina Mirzaian
Saskia M Rombach
Sijmen Kuiper
P2860
P304
P356
10.1371/JOURNAL.PONE.0047805
P407
P577
2012-10-19T00:00:00Z